227 related articles for article (PubMed ID: 19068666)
1. Value of conventional pap smear, liquid-based cytology, visual inspection and human papillomavirus testing as optional screening tools among latin american women <35 and > or =35 years of age: experience from the Latin American Screening Study.
Syrjänen K; Derchain S; Roteli-Martins C; Longatto-Filho A; Hammes LS; Sarian L;
Acta Cytol; 2008; 52(6):641-53. PubMed ID: 19068666
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
[TBL] [Abstract][Full Text] [Related]
3. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS study.
Syrjänen K; Naud P; Derchain S; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Hammes LS; Matos J; Gontijo R; Sarian L; Braganca J; Arlindo FC; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S
Anticancer Res; 2005; 25(5):3469-80. PubMed ID: 16101165
[TBL] [Abstract][Full Text] [Related]
4. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
5. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
[TBL] [Abstract][Full Text] [Related]
6. Screening for cervical cancer in high-risk populations: DNA pap test or Hybrid Capture II test alone?
Miranda Pereira SM; Castelo A; Makabe S; Utagawa ML; Di Loreto C; Sakamoto Maeda MY; Marques JA; Santoro CL; Filho AL; Das Dores GB
Int J Gynecol Pathol; 2006 Jan; 25(1):38-41. PubMed ID: 16306782
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of high-risk human papillomavirus in women with abnormal and normal vaginal ThinPrep Papanicolaou cytology.
Bansal M; Zhao C
J Low Genit Tract Dis; 2011 Apr; 15(2):105-9. PubMed ID: 21317806
[TBL] [Abstract][Full Text] [Related]
8. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
[TBL] [Abstract][Full Text] [Related]
9. Conventional Pap smear and liquid-based cytology as screening tools in low-resource settings in Latin America: experience of the Latin American screening study.
Longatto-Filho A; Maeda MY; Erzen M; Branca M; Roteli-Martins C; Naud P; Derchain SF; Hammes L; Matos J; Gontijo R; Sarian LO; Lima TP; Tatti S; Syrjänen S; Syrjänen K
Acta Cytol; 2005; 49(5):500-6. PubMed ID: 16334026
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
[TBL] [Abstract][Full Text] [Related]
11. Self-sampling for human papillomavirus (HPV) testing as cervical cancer screening option. Experience from the LAMS study.
Longatto-Filho A; Roteli-Martins C; Hammes L; Etlinger D; Pereira SM; Erzen M; Branca M; Naud P; Derchain SF; Sarian LO; Matos J; Gontijo R; Lima T; Maeda MY; Tatti S; Syrjänen S; Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(4):327-32. PubMed ID: 18714563
[TBL] [Abstract][Full Text] [Related]
12. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries?
Bhatla N; Dar L; Patro AR; Kumar P; Kriplani A; Gulati A; Iyer VK; Mathur SR; Sreenivas V; Shah KV; Gravitt PE
Cancer Epidemiol; 2009 Dec; 33(6):446-50. PubMed ID: 19931499
[TBL] [Abstract][Full Text] [Related]
13. Cytology versus HPV testing for cervical cancer screening in the general population.
Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
[TBL] [Abstract][Full Text] [Related]
14. [Investigation of human papillomavirus prevalence in women in Eskişehir, Turkey by Pap smear, hybrid capture 2 test and consensus real-time polymerase chain reaction and typing with pyrosequencing method].
Aslan FG; Us T; Kaşifoğlu N; Özalp SS; Akgün Y; Öge T
Mikrobiyol Bul; 2016 Jan; 50(1):73-85. PubMed ID: 27058331
[TBL] [Abstract][Full Text] [Related]
15. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection.
Nieves L; Enerson CL; Belinson S; Brainard J; Chiesa-Vottero A; Nagore N; Booth C; Pérez AG; Chávez-Avilés MN; Belinson J
Int J Gynecol Cancer; 2013 Mar; 23(3):513-8. PubMed ID: 23334437
[TBL] [Abstract][Full Text] [Related]
16. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
[TBL] [Abstract][Full Text] [Related]
17. Optional screening strategies for cervical cancer using standalone tests and their combinations among low- and medium-income populations in Latin America and Eastern Europe.
Sarian LO; Derchain S; Shabalova I; Tatti S; Naud P; Longatto-Filho A; Syrjänen S; Syrjänen K; ;
J Med Screen; 2010; 17(4):195-203. PubMed ID: 21258130
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
19. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
[TBL] [Abstract][Full Text] [Related]
20. Combined Pap smear, cervicography and HPV DNA testing in the detection of cervical intraepithelial neoplasia and cancer.
Costa S; Sideri M; Syrjänen K; Terzano P; De Nuzzo M; De Simone P; Cristiani P; Finarelli AC; Bovicelli A; Zamparelli A; Bovicelli L
Acta Cytol; 2000; 44(3):310-8. PubMed ID: 10833984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
